Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 10Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Arthritis, Rheumatoid 7Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 5Lymphoma 5Solid Tumors 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Melanoma 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Colorectal Neoplasms 4Ovarian Neoplasms 3Lymphoma, Follicular 3Leukemia 3Hematologic Neoplasms 3Cytokine Release Syndrome 3Burkitt Lymphoma 3Urinary Bladder Neoplasms 2Respiratory Distress Syndrome 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Fallopian Tube Neoplasms 2Craniopharyngioma 2Carcinoma, Hepatocellular 2

Interventions

Carboplatin 159Paclitaxel 153Bevacizumab 85Taxes 48Gemcitabine 48liposomal doxorubicin 47Topotecan 41Cisplatin 35pembrolizumab 33Cyclophosphamide 27olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 21Drug Therapy 20Docetaxel 20niraparib 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 14rucaparib 13Nivolumab 12Cytoreduction Surgical Procedures 11Chemotherapy, Adjuvant 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × tocilizumab × Clear all
NCT03564340 2026-05-08

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
890 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05769959 2024-07-09

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
3 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡